Telaprevir for previously untreated chronic hepatitis C virus infection

Clicks: 486
ID: 114486
2011
Telaprevir with peginterferon-ribavirin, as compared with peginterferon-ribavirin alone, was associated with significantly improved rates of sustained virologic response in patients with HCV genotype 1 infection who had not received previous treatment, with only 24 weeks of therapy administered in t …
Reference Key
im2011thetelaprevir Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jacobson IM;McHutchison JG;Dusheiko G;Di Bisceglie AM;Reddy KR;Bzowej NH;Marcellin P;Muir AJ;Ferenci P;Flisiak R;George J;Rizzetto M;Shouval D;Sola R;Terg RA;Yoshida EM;Adda N;Bengtsson L;Sankoh AJ;Kieffer TL;George S;Kauffman RS;Zeuzem S; ;;
Journal The New England journal of medicine
Year 2011
DOI DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/21696307
Keywords
hepatitis c National Center for Biotechnology Information NCBI NLM MEDLINE RNA humans pubmed abstract nih national institutes of health national library of medicine logistic models research support non-u.s. gov't adult female male aged middle aged young adult Clinical Trial Phase III Randomized Controlled Trial Double-Blind Method Multicenter Study DNA Sequence Analysis viral / blood drug therapy combination antiviral agents / therapeutic use* recombinant proteins viral load hepacivirus / isolation & purification chronic / virology antiviral agents / adverse effects pmid:21696307 doi:10.1056/nejmoa1012912 ira m jacobson john g mchutchison advance study team hepacivirus / genetics* chronic / drug therapy* interferon alpha-2 interferon-alpha / adverse effects interferon-alpha / therapeutic use* oligopeptides / adverse effects oligopeptides / therapeutic use* polyethylene glycols / adverse effects polyethylene glycols / therapeutic use* serine proteinase inhibitors / adverse effects serine proteinase inhibitors / therapeutic use*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.